The anthracyclines: When good things go bad

Cardiovascular Toxicology

Volumn 7, Issue 2, 2007, Pages 53-55

  Minotti, Giorgio ^a,b   Sarvazyan, Narine ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIOXIDANT; FLAVONOID; PHOSPHOLIPASE A2; RAZOXANE; TAXANE DERIVATIVE; TRASTUZUMAB;

CANCER THERAPY; CARDIOTOXICITY; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEMATOLOGIC MALIGNANCY; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; PRIORITY JOURNAL; SOLID TUMOR;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS;

EID: 34548301546     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-007-0017-1     Document Type: Conference Paper

References (20)

1. Cortés-Funes, H., & Coronado, C. (2007). Role of anthracyclines in the era of targeted therapy. Cardiovascular Toxicology, 7(1), in press.
2. Christian Zuppinger, C., Timolati, F., & Suter, T. M. (2007). Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovascular Toxicology, 7(1), in press.
3. Gianni, L., Salvatorelli, E., & Minotti, G. (2007). Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes. Cardiovascular Toxicology, 7(1), in press.
4. Batist, G. (2007). Cardiac safety of liposomal anthracyclines. Cardiovascular Toxicology, 7(1), in press.
5. Sessa, S., Valota, O., & Geroni, C. (2007). Ongoing phase I and II studies of novel anthracyclines Cardiovascular Toxicology, 7(1), in press.
6. Menna, P., Recalcati, S., Cairo, G., & Minotti, G. (2007). An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovascular Toxicology, 7(1), in press.
7. 2 inhibition. Cardiovascular Toxicology, 7(1), in press.
8. Kalyanaraman, B. (2007). Iron signalling and oxidant damage. Cardiovascular Toxicology, 7(1), in press.
9. Kang, Y. J. (2007). Antioxidant defense against anthracycline cardiotoxicity by metallothionein. Cardiovascular Toxicology, 7(1), in press.
10. Wallace, K. B. (2007). Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovascular Toxicology, 7(1), in press.
11. Lebrecht, D., & Walker, U. A. (2007). Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovascular Toxicology, 7(1), in press.
12. Chen, B., Peng, X., Pentassuglia, L., Lim, C. C., & Sawyer, D. B. (2007). Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovascular Toxicology, 7(1), in press.
13. Scully, R. E., & Lipshultz, S. E. (2007). Anthracycline cardio-toxicity in long-term survivors of childhood cancer. Cardiovascular Toxicology, 7(1), in press.
14. Deng, S., & Wojnowski, L. (2007). Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovascular Toxicology, 7(1), in press.
15. Robert, J. (2007). Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovascular Toxicology, 7(1), in press.
16. Herman, H. E., & Hasinoff, B. B. (2007). Dexrazoxane: How it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovascular Toxicology, 7(1), in press.
17. Kaiserová, H., Šimůnek, T., Štěrba, M., den Hartog, G. J. M, Schröterová, L., Popelová, O., Geršl, V., Kvasničková, V., & Bast, A. (2007). New iron chelators in anthracycline-induced cardiotoxicity . Cardiovascular Toxicology, 7(1), in press.
18. Langer, S. W., Jensen, P. B., & Sehested, M. (2007). Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries. Cardiovascular Toxicology, 7(1), in press.
19. Bast, A., Haenen, G. R. M. M, Bruynzeel, A. M. E., & Van der Vijgh, W. J. F. (2007). Protection by flavonoids against anthracycline cardiotoxicity: From chemistry to clinical trials. Cardiovascular Toxicology, 7(1), in press.
20. Hideg, K., & Kála, T. (2007). Novel antioxidants in anthracycline cardiotoxicity. Cardiovascular Toxicology, 7(1), in press.